Dr Amol Akhade· @SuyogCancer · X·· 13 小时前评分70
正文 · 机器翻译
DeLLphi-305。令人印象深刻的曲线。还需观察现实世界中的额外毒性和成本。对广泛型 SCLC 患者有益 @myESMO @OncoAlert #esmo26
348 浏览 · 8 赞 · 5 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Dr Amol Akhade · x.com